CK2 Suppression of Apoptosis and Its Implication in Cancer Biology and Therapy

Protein Kinase CK2

Volumn , Issue , 2013, Pages 319-343

  Trembley, Janeen H ^a   Wu, Jing Jiang ^a   Unger, Gretchen M ^b   Kren, Betsy T ^a   Ahmed, Khalil ^a,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b GeneSegues   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Apoptosis; Cancer biology; Cancer therapy; Cell death; Cell growth; CK2 dynamics

Indexed keywords

EID: 84886833988     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118482490.ch12     Document Type: Chapter

References (152)

1. Afonyushkin T, Oskolkova OV, Binder BR, Bochkov VN. 2011. Involvement of CK2 in activation of electrophilic genes in endothelial cells by oxidized phospholipids. J Lipid Res 52(1):98-103.
2. Afzal A, Shaw LC, Ljubimov AV, Boulton ME, Segal MS, Grant MB. 2007. Retinal and choroidal microangiopathies: therapeutic opportunities. Microvasc Res 74(2-3): 131-144.
3. Ahmad KA, Harris NH, Johnson AD, Lindvall HC, Wang G, Ahmed K. 2007. Protein kinase CK2 modulates apoptosis induced by resveratrol and epigallocatechin-3-gallate in prostate cancer cells. Molecular Cancer Therapeutics 6(3):1006-1012.
4. Ahmad KA, Wang G, Ahmed K. 2006. Intracellular hydrogen peroxide production is an upstream event in apoptosis induced by down-regulation of casein kinase 2 in prostate cancer cells. Molecular cancer research: MCR 4(5):331-338.
5. Ahmad KA, Wang G, Slaton J, Unger G, Ahmed K. 2005. Targeting CK2 for cancer therapy. Anticancer Drugs 16(10):1037-1043.
6. Ahmad KA, Wang G, Unger G, Slaton J, Ahmed K. 2008. Protein kinase CK2-a key sup- pressor of apoptosis. Adv Enzyme Regul 48:179-187.
7. Ahmed K. 1999. Nuclear matrix and protein kinase CK2 signaling. Crit Rev Eukaryot Gene Expr 9(3-4):329-336.
8. Ahmed K. 2012. Nanocapsules. Encyclopedia of Cancer: SpringerReference (www. springerreference.com). M. Schwab. Heidelberg, Springer-Verlag Berlin Heidelberg: 1.
9. Ahmed K, Davis AT, Wang H, Faust RA, Yu S, Tawfic S. 2000. Significance of protein kinase CK2 nuclear signaling in neoplasia. J Cell Biochem Suppl Suppl 35:130-135.
10. Ahmed K, Gerber DA, Cochet C. 2002. Joining the cell survival squad: an emerging role for protein kinase CK2. Trends Cell Biol 12(5):226-230.
11. Ahmed K, Ishida H. 1971. Effect of testosterone on nuclear phosphoproteins of rat ventral prostate. Mol Pharmacol 7(3):323-327.
12. Ahmed K, Tawfic S. 1994. Mechanism of intracellular regulation of protein kinase CK2: role of stimulus-mediated subnuclear association. Cell Mol Biol Res 40(5-6):539-545.
13. Ahmed K, Yenice S, Davis A, Goueli SA. 1993. Association of casein kinase 2 with nuclear chromatin in relation to androgenic regulation of rat prostate. Proc Natl Acad Sci USA 90(10):4426-4430.
14. Allende-Vega N, McKenzie L, Meek D. 2008. Transcription factor TAFII250 phosphorylates the acidic domain of Mdm2 through recruitment of protein kinase CK2. Mol Cell Biochem 316(1-2):99-106.
15. Ampofo E, Kietzmann T, Zimmer A, Jakupovic M, Montenarh M, Gotz C. 2010. Phosphory- lation of the von Hippel-Lindau protein (VHL) by protein kinase CK2 reduces its protein stability and affects p53 and HIF-1alpha mediated transcription. Int J Biochem Cell Biol 42(10):1729-1735.
16. Aukhil I, Joshi P, Yan Y, Erickson HP. 1993. Cell- and heparin-binding domains of the hexabrachion arm identified by tenascin expression proteins. J Biol Chem 268(4): 2542-2553.
17. Barrett RM, Colnaghi R, Wheatley SP. 2011. Threonine 48 in the BIR domain of survivin is critical to its mitotic and anti-apoptotic activities and can be phosphorylated by CK2 in vitro. Cell cycle 10(3):538-548.
18. Belguise K, Guo S, Yang S, Rogers AE, Seldin DC, Sherr DH, Sonenshein GE. 2007. Green tea polyphenols reverse cooperation between c-Rel and CK2 that induces the aryl hydro- carbon receptor, slug, and an invasive phenotype. Cancer Res 67(24):11742-11750.
19. Berges RR, Furuya Y, Remington L, English HF, Jacks T, Isaacs JT. 1993. Cell prolifeation, DNA repair, and p53 function are not required for programmed death of prostatic glan-dular cells induced by androgen ablation. Proceedings of the National Academy of Sci- ences of the United States of America 90(19):8910-8914.
20. Bernatik O, Ganji RS, Dijksterhuis JP, Konik P, Cervenka I, Polonio T, Krejci P, Schulte G, Bryja V. 2011. Sequential activation and inactivation of Dishevelled in the Wnt/beta- catenin pathway by casein kinases. The Journal of biological chemistry 286(12): 10396-10410.
21. Brenneisen P, Wlaschek M, Schwamborn E, Schneider LA, Ma W, Sies H, Scharffetter- Kochanek K. 2002. Activation of protein kinase CK2 is an early step in the ultraviolet B-mediated increase in interstitial collagenase (matrix metalloproteinase-1; MMP-1) and stromelysin-1 (MMP-3) protein levels in human dermal fibroblasts. Biochem J 365 (Pt 1):31-40.
22. Brown MS, Diallo OT, Hu M, Ehsanian R, Yang X, Arun P, Lu H, Korman V, Unger G, Ahmed K, Van Waes C, Chen Z. 2010. CK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules. Clinical cancer research: an official journal of the American Association for Cancer Research 16(8):2295-2307.
23. Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JFM. 2008. The PTEN/PI3K/AKT Signaling Pathway in Cancer, Therapeutic Implications. Current Cancer Drug Targets 8(3):187-198.
24. Carver LA, Schnitzer JE. 2003. Caveolae: mining little caves for new cancer targets. Nat Rev Cancer 3(8):571-581.
25. Chakraborty A, Werner JK, Jr., Koldobskiy MA, Mustafa AK, Juluri KR, Pietropaoli J, Snowman AM, Snyder SH. 2011. Casein kinase-2 mediates cell survival through phos- phorylation and degradation of inositol hexakisphosphate kinase-2. Proceedings of the National Academy of Sciences of the United States of America 108(6):2205-2209.
26. Channavajhala P, Seldin DC. 2002. Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis. Oncogene 21(34):5280-5288.
27. Cobb LJ, Mehta H, Cohen P. 2009. Enhancing the apoptotic potential of insulin-like growth factor-binding protein-3 in prostate cancer by modulation of CK2 phosphorylation. Molecular endocrinology 23(10):1624-1633.
28. Cox ML, Meek DW. 2010. Phosphorylation of serine 392 in p53 is a common and integral event during p53 induction by diverse stimuli. Cell Signal 22(3):564-571.
29. Davis AT, Wang H, Zhang P, Ahmed K. 2002. Heat shock mediated modulation of protein kinase CK2 in the nuclear matrix. J Cell Biochem 85(3):583-591.
30. De Amicis F, Giordano F, Vivacqua A, Pellegrino M, Panno ML, Tramontano D, Fuqua SA, Ando S. 2011. Resveratrol, through NF-Y/p53/Sin3/HDAC1 complex phosphorylation,inhibits estrogen receptor alpha gene expression via p38MAPK/CK2 signaling in human breast cancer cells. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 25(10):3695-3707.
31. Deshiere A, Duchemin-Pelletier E, Spreux E, Ciais D, Forcet C, Cochet C, Filhol O. 2011. Regulation of epithelial to mesenchymal transition: CK2beta on stage. Molecular and cellular biochemistry 356(1-2):11-20.
32. Deshiere A, Theis-Febvre N, Martel V, Cochet C, Filhol O. 2008. Protein kinase CK2 and cell polarity. Molecular and cellular biochemistry 316(1-2):107-113.
33. Di Maira G, Salvi M, Arrigoni G, Marin O, Sarno S, Brustolon F, Pinna LA, Ruzzene M. 2005. Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ 12(6):668-677.
34. Duncan JS, Turowec JP, Duncan KE, Vilk G, Wu C, Luscher B, Li SS, Gloor GB, Litchfield DW. 2011. A peptide-based target screen implicates the protein kinase CK2 in the global regulation of caspase signaling. Science signaling 4(172):ra30.
35. Eddy SF, Guo S, Demicco EG, Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Sonenshein GE. 2005. Inducible IkB Kinase/IkB Kinase {varepsilon} Expression Is Induced by CK2 and Promotes Aberrant Nuclear Factor-kB Activation in Breast Cancer Cells. Cancer Res 65(24):11375-11383.
36. English HF, Kyprianou N, Isaacs JT. 1989. Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. The Prostate 15(3):233-250.
37. Erickson HP, Bourdon MA. 1989. Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors. Annu Rev Cell Biol 5:71-92.
38. Evan GI, Vousden KH. 2001. Proliferation, cell cycle and apoptosis in cancer. Nature 411(6835):342-348.
39. Faust M, Montenarh M. 2000. Subcellular localization of protein kinase CK2. A key to its function? Cell Tissue Res 301(3):329-340.
40. Faust RA, Gapany M, Tristani P, Davis A, Adams GL, Ahmed K. 1996. Elevated protein kinase CK2 activity in chromatin of head and neck tumors: association with malignant transformation. Cancer Lett 101(1):31-35.
41. Faust M, Montenarh M. 2000. Subcellular localization of protein kinase CK2. A key to its function? Cell Tissue Res 301(3):329-340.
42. Faust RA, Niehans G, Gapany M, Hoistad D, Knapp D, Cherwitz D, Davis A, Adams GL, Ahmed K. 1999. Subcellular immunolocalization of protein kinase CK2 in normal and carcinoma cells. Int J Biochem Cell Biol 31(9):941-949.
43. Feng D, Welker S, Korbel C, Rudzitis-Auth J, Menger MD, Montenarh M, Laschke MW. 2012. Protein kinase CK2 is a regulator of angiogenesis in endometriotic lesions. Angiogenesis.
44. Friedman J, Nottingham L, Duggal P, Pernas FG, Yan B, Yang XP, Chen Z, Van Waes C. 2007. Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacriin head and neck cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 13(22 Pt 1):6568-6578.
45. Gapany M, Faust RA, Tawfic S, Davis A, Adams GL, Ahmed K. 1995. Association of elevated protein kinase CK2 activity with aggressive behavior of squamous cell carcinoma of the head and neck. Mol Med 1(6):659-666.
46. Gerber DA, Souquere-Besse S, Puvion F, Dubois MF, Bensaude O, Cochet C. 2000. Heat- induced relocalization of protein kinase CK2. Implication of CK2 in the context of cellular stress. The Journal of biological chemistry 275(31):23919-23926.
47. Giusiano S, Cochet C, Filhol O, Duchemin-Pelletier E, Secq V, Bonnier P, Carcopino X, Boubli L, Birnbaum D, Garcia S, Iovanna J, Charpin C. 2011. Protein kinase CK2alpha subunit over-expression correlates with metastatic risk in breast carcinomas: quantitative immunohistochemistry in tissue microarrays. European journal of cancer 47(5):792-801.
48. Golub AG, Bdzhola VG, Briukhovetska NV, Balanda AO, Kukharenko OP, Kotey IM, Ostrynska OV, Yarmoluk SM. 2011. Synthesis and biological evaluation of substituted (thieno[2,3-d]pyrimidin-4-ylthio)carboxylic acids as inhibitors of human protein kinase CK2. Eur J Med Chem 46(3):870-876.
49. Gotz C, Kartarius S, Schwar G, Montenarh M. (2005) Phosphorylation of mdm2 at serine 269 impairs its interaction with the retinoblastoma protein. Int J Oncol 26(3):801-808.
50. Goueli SA, Ahmed K. 1991. Nature of the intrinsic protein kinases involved in phosphoryla- tion of non-histone proteins in intact prostatic nuclei: further identification of androgen- sensitive protein kinase reactions. Mol Cell Biochem 101(2):145-155.
51. Guerra B, Issinger OG. 1999. Protein kinase CK2 and its role in cellular proliferation, devel- opment and pathology. Electrophoresis 20(2):391-408.
52. Guerra B, Issinger OG. 2008. Protein kinase CK2 in human diseases. Curr Med Chem 15(19):1870-1886.
53. Guo C, Davis AT, Ahmed K. 1998. Dynamics of protein kinase CK2 association with nucleo- somes in relation to transcriptional activity. J Biol Chem 273(22):13675-13680.
54. Guo C, Yu S, Davis AT, Ahmed K. 1999. Nuclear matrix targeting of the protein kinase CK2 signal as a common downstream response to androgen or growth factor stimulation of prostate cancer cells. Cancer Res 59(5):1146-1151.
55. Guo C, Yu S, Davis AT, Wang H, Green JE, Ahmed K. 2001. A potential role of nuclear matrix-associated protein kinase CK2 in protection against drug-induced apoptosis in cancer cells. J Biol Chem 276(8):5992-5999.
56. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100(1):57-70.
57. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144(5):646-674.
58. Hessenauer A, Schneider CC, Götz C, Montenarh M. 2011. CK2 inhibition induces apoptosis via the ER stress response. Cellular Signalling 23(1):145-151.
59. Hjerrild M, Milne D, Dumaz N, Hay T, Issinger OG, Meek D. 2001. Phosphorylation of murine double minute clone 2 (MDM2) protein at serine-267 by protein kinase CK2 in vitro and in cultured cells. Biochem J 355(Pt 2):347-356.
60. Homma MK, Li D, Krebs EG, Yuasa Y, Homma Y. 2002. Association and regulation of casein kinase 2 activity by adenomatous polyposis coli protein. Proceedings of the National Academy of Sciences of the United States of America 99(9):5959-5964.
61. Ishida H, Ahmed K. 1974. Studies on chromatin-associated protein phosphokinase of sub- mandibular gland from isoproterenol-treated rats. Exp Cell Res 84(1):127-136.
62. Izeradjene K, Douglas L, Delaney A, Houghton JA. 2004. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhab- domyosarcoma cells. Clin Cancer Res 10(19):6650-6660.
63. Kato T, Jr, Delhase M, Hoffmann A, Karin M. 2003. CK2 Is a C-Terminal IkappaB Kinase Responsible for NF-kappaB Activation during the UV Response. Mol Cell 12(4):829-839.
64. Kelliher MA, Seldin DC, Leder P. 1996. Tal-1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase IIa. EMBO J 15(19):5160-5166.
65. Kerr JF, Wyllie AH, Currie AR. 1972. Apoptosis: a basic biological phenomenon with wide- ranging implications in tissue kinetics. British journal of cancer 26(4):239-257.
66. Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hedge P, McKechnie D, et al. 1991. Identification of FAP locus genes from chromo- some 5q21. Science 253(5020):661-665.
67. Kramerov A, Saghizadeh M, Caballero S, Shaw L, Li Calzi S, Bretner M, Montenarh M, Pinna L, Grant M, Ljubimov A. 2008. Inhibition of protein kinase CK2 suppresses angio- genesis and hematopoietic stem cell recruitment to retinal neovascularization sites. Molecular and Cellular Biochemistry 316(1):177-186.
68. Kramerov AA, Saghizadeh M, Pan H, Kabosova A, Montenarh M, Ahmed K, Penn JS, Chan CK, Hinton DR, Grant MB, Ljubimov AV. 2006. Expression of protein kinase CK2 in astroglial cells of normal and neovascularized retina. Am J Pathol 168(5):1722-1736.
69. Kren BT, Unger GM, Sjeklocha L, Trossen AA, Korman V, Diethelm-Okita BM, Reding MT, Steer CJ. 2009. Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice. J Clin Invest 119(7):2086-2099.
70. Kubler D, Gosenca D, Wind M, Heid H, Friedberg I, Jahnen-Dechent W, Lehmann WD. 2007. Proteolytic processing by matrix metalloproteinases and phosphorylation by protein kinase CK2 of fetuin-A, the major globulin of fetal calf serum. Biochimie 89(3):410-418.
71. Kyprianou N, Bruckheimer EM, Guo Y. 2000. Cell proliferation and apoptosis in prostate cancer: significance in disease progression and therapy. Histol Histopathol 15(4):1211-1223.
72. Landesman-Bollag E, Channavajhala PL, Cardiff RD, Seldin DC. 1998. p53 deficiency and misexpression of protein kinase CK2a collaborate in the development of thymic lympho- mas in mice. Oncogene 16(23):2965-2974.
73. Landesman-Bollag E, Song DH, Romieu-Mourez R, Sussman DJ, Cardiff RD, Sonenshein GE, Seldin DC. 2001. Protein kinase CK2: signaling and tumorigenesis in the mammary gland. Mol Cell Biochem 227(1-2):153-165.
74. Laramas M, Pasquier D, Filhol O, Ringeisen F, Descotes JL, Cochet C. 2007. Nuclear local- ization of protein kinase CK2 catalytic subunit (CK2a) is associated with poor prognostic factors in human prostate cancer. Eur J Cancer 43(5):928-934.
75. Laudet B, Moucadel V, Prudent R, Filhol O, Wong YS, Royer D, Cochet C. 2008. Identifica- tion of chemical inhibitors of protein-kinase CK2 subunit interaction. Molecular and cellular biochemistry 316(1-2):63-69.
76. Lee TL, Yang XP, Yan B, Friedman J, Duggal P, Bagain L, Dong G, Yeh NT, Wang J, Zhou J, Elkahloun A, Van Waes C, Chen Z. 2007. A novel nuclear factor-kappaB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status. Clinical cancer research: an official journal of the American Association for Cancer Research 13(19):5680-5691.
77. Liao S. 1975. Cellular receptors and mechanisms of action of steroid hormones. International review of cytology 41:87-172.
78. Lin KY, Tai C, Hsu JC, Li CF, Fang CL, Lai HC, Hseu YC, Lin YF, Uen YH. 2011. Overex- pression of Nuclear Protein Kinase CK2 alpha Catalytic Subunit (CK2alpha) as a Poor Prognosticator in Human Colorectal Cancer. PloS one 6(2):e17193.
79. Litchfield DW. 2003. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 369(Pt 1):1-15.
80. Liu B, Lee KW, Anzo M, Zhang B, Zi X, Tao Y, Shiry L, Pollak M, Lin S, Cohen P. 2007. Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis. Oncogene 26(12):1811-1819.
81. Loizou JI, El-Khamisy SF, Zlatanou A, Moore DJ, Chan DW, Qin J, Sarno S, Meggio F, Pinna LA, Caldecott KW. 2004. The protein kinase CK2 facilitates repair of chromosomal DNA single-strand breaks. Cell 117(1):17-28.
82. MacPherson MR, Molina P, Souchelnytskyi S, Wernstedt C, Martin-Perez J, Portillo F, Cano A. 2010. Phosphorylation of serine 11 and serine 92 as new positive regulators of human Snail1 function: potential involvement of casein kinase-2 and the cAMP-activated kinase protein kinase A. Molecular biology of the cell 21(2):244-253.
83. Martel V, Filhol O, Nueda A, Cochet C. 2002. Dynamic localization/association of protein kinase CK2 subunits in living cells: a role in its cellular regulation? Annals of the New York Academy of Sciences 973:272-277.
84. McDonnell MA, Abedin MJ, Melendez M, Platikanova TN, Ecklund JR, Ahmed K, Kelekar A. 2008. Phosphorylation of murine caspase-9 by the protein kinase casein kinase 2 regulates its cleavage by caspase-8. The Journal of biological chemistry 283(29):20149-20158.
85. McKendrick L, Milne D, Meek D. 1999. Protein kinase CK2-dependent regulation of p53 function: evidence that the phosphorylation status of the serine 386 (CK2) site of p53 is constitutive and stable. Molecular and cellular biochemistry 191(1-2):187-199.
86. Meggio F, Pinna LA. 2003. One-thousand-and-one substrates of protein kinase CK2? FASEB J. 17(3):349-368.
87. Miller SJ, Lou DY, Seldin DC, Lane WS, Neel BG. 2002. Direct identification of PTEN phosphorylation sites. FEBS Lett 528(1-3):14-153.
88. Mottet D, Ruys SP, Demazy C, Raes M, Michiels C. 2005. Role for casein kinase 2 in the regulation of HIF-1 activity. Int J Cancer 117(5):764-774.
89. O-charoenrat P, Rusch V, Talbot SG, Sarkaria I, Viale A, Socci N, Ngai I, Rao P, Singh B. 2004. Casein kinase II alpha subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung. Clin Cancer Res 10(17):5792-5803.
90. Olsten ME, Weber JE, Litchfield DW. 2005. CK2 interacting proteins: emerging paradigms for CK2 regulation? Mol Cell Biochem 274(1-2):115-124.
91. Pagano MA, Bain J, Kazimierczuk Z, Sarno S, Ruzzene M, Di Maira G, Elliott M, Orzeszko A, Cozza G, Meggio F, Pinna LA. 2008. The selectivity of inhibitors of protein kinase CK2: an update. Biochem J 415(3):353-365.
92. Pando MP, Verma IM. 2000. Signal-dependent and -independent degradation of free and NF-kappa B-bound IkappaBalpha. J Biol Chem 275(28):21278-21286.
93. Perea SE, Baladron I, Garcia Y, Perera Y, Lopez A, Soriano JL, et al. 2011. CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research. . Mol Cell Biochem 356:45-50.
94. Perea SE, Reyes O, Baladron I, Perera Y, Farina H, Gil J, Rodriguez A, Bacardi D, Marcelo JL, Cosme K, Cruz M, Valenzuela C, Lopez-Saura PA, Puchades Y, Serrano JM, Mendoza O, Castellanos L, Sanchez A, Betancourt L, Besada V, Silva R, Lopez E, Falcon V, Hernandez I, Solares M, Santana A, Diaz A, Ramos T, Lopez C, Ariosa J, Gonzalez LJ, Garay H, Gomez D, Gomez R, Alonso DF, Sigman H, Herrera L, Acevedo B. 2008. CIGB- 300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo. Mol Cell Biochem 316:(1-2):163-167.
95. Perea SE, Reyes O, Puchades Y, Mendoza O, Vispo NS, Torrens I, Santos A, Silva R, Acevedo B, Lopez E, Falcon V, Alonso DF. 2004. Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2). Cancer Res 64(19):7127-7129.
96. Perera Y, Farina HG, Gil J, Rodriguez A, Benavent F, Castellanos L.Gomez RE, Acevedo BE, Alonso DF, Perea SE. 2009. Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity. Mol Cancer Ther 8(5):1189-1196.
97. Piazza F, Manni S, Ruzzene M, Pinna LA, Gurrieri C, Semenzato G. 2012. Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by onco- genic signaling pathways. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K.
98. Piazza FA, Ruzzene M, Gurrieri C, Montini B, Bonanni L, Chioetto G, Di Maira G, Barbon F, Cabrelle A, Zambello R, Adami F, Trentin L, Pinna LA, Semenzato G. 2006. Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood 108(5): 1698-1707.
99. Pierre F, Chua PC, O'Brien SE, Siddiqui-Jain A, Bourbon P, Haddach M, Michaux J, Nagasawa J, Schwaebe MK, Stefan E, Vialettes A, Whitten JP, Chen TK, Darjania L, Stansfield R, Bliesath J, Drygin D, Ho C, Omori M, Proffitt C, Streiner N, Rice WG, Ryckman DM, Anderes K. 2011. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer. Molecular and cellular biochemistry 356(1-2):37-43.
100. Pinna LA. 2002 Protein kinase CK2: a challenge to canons. J Cell Sci 115(Pt 20): 3873-3878.
101. Pinna LA, Allende JE. 2009. Protein kinase CK2 in health and disease: Protein kinase CK2: an ugly duckling in the kinome pond. Cell Mol Life Sci 66(11-12):1795-1799.
102. Ponce DP, Yefi R, Cabello P, Maturana JL, Niechi I, Silva E, Galindo M, Antonelli M, Marcelain K, Armisen R, Tapia JC. 2011. CK2 functionally interacts with AKT/PKB to promote the beta-catenin-dependent expression of survivin and enhance cell survival. Molecular and cellular biochemistry 356(1-2):127-132.
103. Prowald A, Schuster N, Montenarh M. 1997. Regulation of the DNA binding of p53 by its interaction with protein kinase CK2. FEBS letters 408(1):99-104.
104. Ravi R, Bedi A. 2002. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II. Cancer Res 62(15):4180-4185.
105. Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Sonenshein GE. 2002. Protein Kinase CK2 Promotes Aberrant Activation of Nuclear Factor-{kappa}B, Transformed Phenotype, and Survival of Breast Cancer Cells. Cancer Res 62(22):6770-6778.
106. Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Traish AM, Mercurio F, Sonenshein GE. 2001. Roles of IKK kinases and protein kinase CK2 in activation of nuclear factor-kB in breast cancer. Cancer Res 61(9):3810-3818.
107. Rozanov DV, Savinov AY, Williams R, Liu K, Golubkov VS, Krajewski S, Strongin AY. 2008. Molecular Signature of MT1-MMP: Transactivation of the Downstream Universal Gene Network in Cancer. Cancer Res 68(11):4086-4096.
108. Ruzzene M, Penzo D, Pinna L.A. 2002. Protein kinase CK2 inhibitor 4,5,6,7- tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. Biochem J 364 (Pt 1):41-47.
109. Ruzzene M, Pinna LA. 2010. Addiction to protein kinase CK2: a common denominator of diverse cancer cells?. Biochim Biophys Acta 1804(3):499-504.
110. Sarno S, Pinna LA. 2008. Protein kinase CK2 as a druggable target. Mol Biosyst 4(9):889-894.
111. Scaglioni PP, Yung TM, Cai LF, Erdjument-Bromage H, Kaufman AJ, Singh B, Teruya- Feldstein J, Tempst P, Pandolfi PP. 2006. A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell 126(2):269-283.
112. Scaglioni PP, Yung TM, Choi S, Baldini C, Konstantinidou G, Pandolfi PP. 2008. CK2 medi- ates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor. Mol Cell Biochem 316(1-2):149-154.
113. Schneider CC, Hessenauer A, Montenarh M, Gotz C. 2010. p53 is dispensable for the induc- tion of apoptosis after inhibition of protein kinase CK2. Prostate 70(2):126-134.
114. Schuster N, Gotz C, Faust M, Schneider E, Prowald A, Jungbluth A, Montenarh M. 2001. Wild-type p53 inhibits protein kinase CK2 activity. J Cell Biochem 81(1):172-183.
115. Seeber S, Issinger OG, Holm T, Kristensen LP, Guerra B. 2005. Validation of protein kinase CK2 as oncological target. Apoptosis 10(4):875-885.
116. Seldin DC, Landesman-Bollag E, Farago M, Currier N, Lou D, Dominguez I. 2005. CK2 as a positive regulator of Wnt signalling and tumourigenesis. Mol Cell Biochem 274(1-2):63-67.
117. Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, O'Brien SE, Bliesath J, Omori M, Huser N, Ho C, Proffitt C, Schwaebe MK, Ryckman DM, Rice WG, Anderes K. 2010. CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy. Cancer Research 70(24):10288-10298.
118. Singh N, Ramji D. 2008. Protein kinase CK2, an important regulator of the inflammatory response? Journal of Molecular Medicine 86(8):887-897.
119. Slaton JW, Unger GM, Sloper DT, Davis AT, Ahmed K. 2004. Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model. Mol Cancer Res 2(12):712-721.
120. Solares AM, Santana A, Baladron I, Valenzuela C, Gonzalez CA, Diaz A, Castillo D, Ramos T, Gomez R, Alonso DF, Herrera L, Sigman H, Perea SE, Acevedo BE, Lopez-Saura P. 2009. Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malig- nancies. BMC Cancer 9:146.
121. Su YW, Xie TX, Sano D, Myers JN. 2011. IL-6 stabilizes Twist and enhances tumor cell motility in head and neck cancer cells through activation of casein kinase 2. PloS one 6(4):e19412.
122. Tapia JC, Torres VA, Rodriguez DA, Leyton L, Quest AF. 2006. Casein kinase 2 (CK2) increases survivin expression via enhanced beta-catenin-T cell factor/lymphoid enhancer binding factor-dependent transcription. Proc Natl Acad Sci USA 103(41):15079-15084.
123. Tawfic S, Ahmed K. 1994. Growth stimulus-mediated differential translocation of casein kinase 2 to the nuclear matrix. Evidence based on androgen action in the prostate. J Biol Chem 269(40):24615-24620.
124. Tawfic S, Faust RA, Gapany M, Ahmed K. 1996. Nuclear matrix as an anchor for protein kinase CK2 nuclear signalling. J Cell Biochem 62(2):165-171.
125. Tawfic S, Yu S, Wang H, Faust R, Davis A, Ahmed K. 2001. Protein kinase CK2 signal in neoplasia. Histol Histopathol 16(2):573-582.
126. Theis-Febvre N, Martel V, Laudet B, Souchier C, Grunwald D, Cochet C, Filhol O. 2005 Highlighting protein kinase CK2 movement in living cells. Molecular and cellular bio- chemistry 274(1-2):15-22.
127. Torres J, Pulido R. 2001. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degrada- tion. J Biol Chem 276(2):993-998.
128. Trembley JH, Chen Z, Unger G, Slaton J, Kren BT, Van Waes C, Ahmed K. 2010. Emergence of protein kinase CK2 as a key target in cancer therapy. BioFactors 36(3):187-195.
129. Trembley JH, Unger GM, Korman VL, Tobolt DK, Kazimierczuk Z, Pinna LA, Kren BT, Ahmed K. 2012. Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells. Cancer letters 315(1):48-58.
130. Trembley JH, Unger GM, Tobolt DK, Korman VL, Wang G, Ahmad KA, Slaton JW, Kren BT, Ahmed K. 2011. Systemic administration of antisense oligonucleotides simul- taneously targeting CK2alpha and alpha' subunits reduces orthotopic xenograft prostate tumors in mice. Molecular and cellular biochemistry 356(1-2):21-35.
131. Trembley JH, Wang G, Unger G, Slaton J, Ahmed K. 2009. Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell Mol Life Sci 66(11-12):1858-1867.
132. Tuxhorn JA, Ayala GE, Rowley DR. 2001. Reactive stroma in prostate cancer progression. J Urol 166(6):2472-2483.
133. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR. 2002. Reactive Stroma in Human Prostate Cancer. Clinical Cancer Research 8(9):2912-2923.
134. Unger G, Trembley J, Kren B, Ahmed K. 2012. Nanoparticles in cancer therapy. Encyclope- dia of Cancer: SpringerReference (www.springerreference.com). M. Schwab. Heidelberg, Springer-Verlag Berlin Heidelberg: 1-4.
135. Unger GM, Davis AT, Slaton JW, Ahmed K. 2004. Protein kinase CK2 as regulator of cell survival: implications for cancer therapy. Curr Cancer Drug Targets 4(1):77-84.
136. Vazquez F, Grossman SR, Takahashi Y, Rokas MV, Nakamura N, Sellers WR. 2001. Phos- phorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem 276(52):48627-48630.
137. Wang D, Westerheide SD, Hanson JL, Baldwin AS Jr. 2000. Tumor necrosis factor alpha- induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II. J Biol Chem 275(42):32592-32597.
138. Wang G, Ahmad KA, Ahmed K. 2005. Modulation of death receptor-mediated apoptosis by CK2. Mol Cell Biochem 274(1-2):201-205.
139. Wang G, Ahmad KA, Ahmed K. 2006. Role of protein kinase CK2 in the regulation of tumor necrosis factor-related apoptosis inducing ligand-induced apoptosis in prostate cancer cells. Cancer Res 66(4):2242-2249.
140. Wang G, Ahmad KA, Harris NH, Ahmed K. 2008. Impact of protein kinase CK2 on inhibitor of apoptosis proteins in prostate cancer cells. Mol Cell Biochem 316(1-2):91-97.
141. Wang G, Pan Y, Ahmad KA, Ahmed K. 2010. Protein B23/nucleophosmin/numatrin nuclear dynamics in relation to protein kinase CK2 and apoptotic activity in prostate cells. Biochemistry 49(18):3842-3852.
142. Wang G, Unger G, Ahmad KA, Slaton JW, Ahmed K. 2005. Downregulation of CK2 induces apoptosis in cancer cells-a potential approach to cancer therapy. Mol Cell Biochem 274(1-2):77-84.
143. Wang H, Davis A, Yu S, Ahmed K. 2001. Response of cancer cells to molecular interruption of the CK2 signal. Mol Cell Biochem 227(1-2):167-174.
144. Williams-Ashman HG, Reddi AH. 1971. Actions of vertebrate sex hormones. Annual review of physiology 33:31-82.
145. Yamane K, Kinsella TJ. 2005. CK2 inhibits apoptosis and changes its cellular localization following ionizing radiation. Cancer Res 65(10):4362-4367.
146. Yanagawa T, Funasaka T, Tsutsumi S, Raz T, Tanaka N, Raz A. 2005. Differential regulation of phosphoglucose isomerase/autocrine motility factor activities by protein kinase CK2 phosphorylation. The Journal of biological chemistry 280(11):10419-10426.
147. Yata K, Lloyd J, Maslen S, Bleuyard JY, Skehel M, Smerdon SJ, Esashi F. 2012. Plk1 and CK2 act in concert to regulate Rad51 during DNA double strand break repair. Molecular cell 45(3):371-383.
148. Yenice S, Davis AT, Goueli SA, Akdas A, Limas C, Ahmed K. 1994. Nuclear casein kinase 2 (CK-2) activity in human normal, benign hyperplastic, and cancerous prostate. Prostate 24(1):11-16.
149. Yokoyama K, Erickson HP, Ikeda Y, Takada Y. 2000. Identification of amino acid sequences in fibrinogen gamma-chain and tenascin C C-terminal domains critical for binding to integrin alpha vbeta 3. J Biol Chem 275(22):16891-16898.
150. Yu M, Yeh J, Van Waes C. 2006. Protein kinase casein kinase 2 mediates inhibitor-kappaB kinase and aberrant nuclear factor-kappaB activation by serum factor(s) in head and neck squamous carcinoma cells. Cancer Res 66(13):6722-6731.
151. Zheng Y, Qin H, Frank SJ, Deng L, Litchfield DW, Tefferi A, Pardanani A, Lin FT, Li J, Sha B, Benveniste EN. 2011. A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway. Blood 118(1):156-166.
152. Zou J, Luo H, Zeng Q, Dong Z, Wu D, Liu L. 2011. Protein kinase CK2a is overexpressed in colorectal cancer and modulates cell proliferation and invasion via regulating EMT- related genes. Journal of Translational Medicine 9:1-11.